Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab intravitreal injection for severe nonproliferative and mild proliferative diabetic retinopathy
ChiCTR2000030434Phase 4Recruiting
- Sponsor
- Wenzhou Medical University
- Start
- Mar 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in diabetic retinopathy (DR), sponsored by Wenzhou Medical University. Primary endpoint: Rate of 2-level regression in diabetic retinopathy severity score on ETDRS seven-field color fundus photographs. Started Mar 2020; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on ChiCTR2000030434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030434.